<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32761823</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2021</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5381</ISSN><JournalIssue CitedMedium="Internet"><Volume>178</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>British journal of pharmacology</Title><ISOAbbreviation>Br J Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Sigma 1 receptor as a therapeutic target for amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1336</StartPage><EndPage>1352</EndPage><MedlinePgn>1336-1352</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bph.15224</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is an adult disease causing a progressive loss of upper and lower motoneurons, muscle paralysis and early death. ALS has a poor prognosis of 3-5 years after diagnosis with no effective cure. The aetiopathogenic mechanisms involved include glutamate excitotoxicity, oxidative stress, protein misfolding, mitochondrial alterations, disrupted axonal transport and inflammation. Sigma non-opioid intracellular receptor 1 (sigma 1 receptor) is a protein expressed in motoneurons, mainly found in the endoplasmic reticulum (ER) on the mitochondria-associated ER membrane (MAM) or in close contact with cholinergic postsynaptic sites. MAMs are sites that allow the assembly of several complexes implicated in essential survival cell functions. The sigma 1 receptor modulates essential mechanisms for motoneuron survival including excitotoxicity, calcium homeostasis, ER stress and mitochondrial dysfunction. This review updates sigma 1 receptor mechanisms and its alterations in ALS, focusing on MAM modulation, which may constitute a novel target for therapeutic strategies. LINKED ARTICLES: This article is part of a themed issue on Neurochemistry in Japan. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v178.6/issuetoc.</AbstractText><CopyrightInformation>&#xa9; 2020 The British Pharmacological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herrando-Grabulosa</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neurosciences, Department Cell Biology, Physiology and Immunology, Universitat Aut&#xf2;noma de Barcelona, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaja-Capdevila</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0028-570X</Identifier><AffiliationInfo><Affiliation>Institute of Neurosciences, Department Cell Biology, Physiology and Immunology, Universitat Aut&#xf2;noma de Barcelona, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vela</LastName><ForeName>Jos&#xe9; M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Esteve Pharmaceuticals S.A., Drug Discovery and Preclinical Development, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0001-9849-902X</Identifier><AffiliationInfo><Affiliation>Institute of Neurosciences, Department Cell Biology, Physiology and Immunology, Universitat Aut&#xf2;noma de Barcelona, Bellaterra, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n Biom&#xe9;dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institut Guttmann de Neurorehabilitaci&#xf3;, Badalona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TERCEL (RD16/0011/0014)</GrantID><Agency>Instituto de Salud Carlos III of Spain</Agency><Country/></Grant><Grant><GrantID>CIBERNED (CB06/05/1105)</GrantID><Agency>Instituto de Salud Carlos III of Spain</Agency><Country/></Grant><Grant><GrantID>RTI2018-096386-B-I00</GrantID><Agency>Ministerio de Ciencia, Innovaci&#xf3;n y Universidades of Spain</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Pharmacol</MedlineTA><NlmUniqueID>7502536</NlmUniqueID><ISSNLinking>0007-1188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017480">Receptors, sigma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004721" MajorTopicYN="N">Endoplasmic Reticulum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059865" MajorTopicYN="N">Endoplasmic Reticulum Stress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017480" MajorTopicYN="Y">Receptors, sigma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">calcium homeostasis</Keyword><Keyword MajorTopicYN="N">motoneuron</Keyword><Keyword MajorTopicYN="N">neurodegenerative diseases</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword><Keyword MajorTopicYN="N">sigma 1 receptor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32761823</ArticleId><ArticleId IdType="doi">10.1111/bph.15224</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Abraham, M. J., Wong, A. Y., &amp; Bergeron, R. (2017). Differential regulation of delayed rectifying voltage-gated potassium channel dynamics by the mutant sigma1-receptor underlying ALS16. Soc Neurosci Meeting, 375.28/E4.</Citation></Reference><Reference><Citation>Alexander, S. P. H., Kelly, E., Mathie, A., Peters, J., Veale, E. L., Armstrong, J. A., &#x2026; Southan, C. (2019). The concise guide to pharmacology 2019/20: Introduction and other protein targets. British Journal of Pharmacology, 176, S1-S20.</Citation></Reference><Reference><Citation>Alexander, S. P. H., Cidlowski, J. A., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., &#x2026; GTP collaborators. (2019). The concise guide to pharmacology 2019/2020: Nuclear hormones receptors. British Journal of Pharmacology, 176, S229-S246. https://doi.org/10.1111/bph.14748</Citation></Reference><Reference><Citation>Al-Saif, A., Al-Mohanna, F., &amp; Bohlega, S. (2011). A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Annals of Neurology, 70, 913-919.</Citation></Reference><Reference><Citation>Babin, P. J., Goizet, C., &amp; Rald&#xfa;a, D. (2014). Zebrafish models of human motor neuron diseases: Advantages and limitations. Progress in Neurobiology, 118, 36-58.</Citation></Reference><Reference><Citation>Balasuriya, D., Stewart, A. P., &amp; Edwardson, J. M. (2013). The &#x3c3;-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1/GluN2A NMDA receptor. The Journal of Neuroscience, 33, 18219-18224.</Citation></Reference><Reference><Citation>Bartok, A., Weaver, D., Golen&#xe1;r, T., Nichtova, Z., Katona, M., &amp; B&#xe1;ns&#xe1;ghi, S. (2019). IP(3) receptor isoforms differently regulate ER-mitochondrial contacts and local calcium transfer. Nature Communications, 10, 3726. https://doi.org/10.1038/s41467-019-11646-3</Citation></Reference><Reference><Citation>Batra, R., &amp; Lee, C. W. (2017). Mouse models of C9orf72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis/frontotemporal dementia. Frontiers in Cellular Neuroscience, 11, 196.</Citation></Reference><Reference><Citation>Bernard-Marissal, N., M&#xe9;dard, J. J., Azzedine, H., &amp; Chrast, R. (2015). Dysfunction in endoplasmic reticulum-mitochondria crosstalk underlies SIGMAR1 loss of function mediated motor neuron degeneration. Brain, 138, 875-890. https://doi.org/10.1093/brain/awv008</Citation></Reference><Reference><Citation>Boillee, S., Vandervelde, C., &amp; Cleveland, D. (2006). ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron, 52, 39-59. https://doi.org/10.1016/j.neuron.2006.09.018</Citation></Reference><Reference><Citation>Bosco, D. A., Morfini, G., Karabacak, N. M., Song, Y., Gros-Louis, F., Pasinelli, P., &#x2026; Brown, R. H. Jr. (2010). Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nature Neuroscience, 13, 1396-1403. https://doi.org/10.1038/nn.2660</Citation></Reference><Reference><Citation>Cai, Y., Arikkath, J., Yang, L., Guo, M.-L., Periyasamy, P., &amp; Buch, S. (2016). Interplay of endoplasmic reticulum stress and autophagy in neurodegenerative disorders. Autophagy, 12, 225-244.</Citation></Reference><Reference><Citation>Cai, Y., Yang, L., Niu, F., Liao, K., &amp; Buch, S. (2017). Role of sigma-1 receptor in cocaine abuse and neurodegenerative disease. Advances in Experimental Medicine and Biology, 964, 163-175.</Citation></Reference><Reference><Citation>Casanovas, A., Salvany, S., Lahoz, V., Tarabal, O., Piedrafita, L., Sabater, R., &#x2026; Esquerda, J. E. (2017). Neuregulin 1-ErbB module in C-bouton synapses on somatic motor neurons: Molecular compartmentation and response to peripheral nerve injury. Scientific Reports, 7, 40155.</Citation></Reference><Reference><Citation>Casas, C., Herrando-Grabulosa, M., Manzano, R., Mancuso, R., Osta, R., &amp; Navarro, X. (2013). Early presymptomatic cholinergic dysfunction in a murine model of amyotrophic lateral sclerosis. Brain and Behavior: A Cognitive Neuroscience Perspective, 3, 145-158.</Citation></Reference><Reference><Citation>Cerver&#xf3;, C., Blasco, A., Tarabal, O., Casanovas, A., Piedrafita, L., Navarro, X., &#x2026; Calder&#xf3;, J. (2018). Glial activation and central synapse loss, but not motoneuron degeneration, are prevented by the sigma-1 receptor agonist PRE-084 in the Smn2B/&#x2212; mouse model of spinal muscular atrophy. Journal of Neuropathology and Experimental Neurology, 77, 577-597. https://doi.org/10.1093/jnen/nly033</Citation></Reference><Reference><Citation>Christ, M. G., Huesmann, H., Nagel, H., Kern, A., &amp; Behl, C. (2019). Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo. Cell, 8, 211. https://doi.org/10.3390/cells8030211</Citation></Reference><Reference><Citation>Clement, A. M., Nguyen, M. D., Roberts, E. A., Garcia, M. L., Boill&#xe9;e, S., Rule, M., &#x2026; Cleveland, D. W. (2003). Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science, 302, 113-117. https://doi.org/10.1126/science.1086071</Citation></Reference><Reference><Citation>Couly, S., Khalil, B., Viguier, V., Roussel, J., Maurice, T., &amp; Li&#xe9;vens, J. C. (2020). Sigma-1 receptor is a key genetic modulator in amyotrophic lateral sclerosis. Human Molecular Genetics, 29, 529-540.</Citation></Reference><Reference><Citation>Dadon-Nachum, M., Melamed, E., &amp; Offen, D. (2011). The &#x201c;dying-back&#x201d; phenomenon of motor neurons in ALS. Journal of Molecular Neuroscience, 43, 470-477.</Citation></Reference><Reference><Citation>De Brito, O. M., &amp; Scorrano, L. (2008). Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature, 456, 605-610.</Citation></Reference><Reference><Citation>De Vos, K. J., M&#xf3;rotz, G. M., Stoica, R., Tudor, E. L., Lau, K. F., Ackerley, S., &#x2026; Miller, C. C. (2012). VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis. Human Molecular Genetics, 21, 1299-1311.</Citation></Reference><Reference><Citation>Deardorff, A. S., Romer, S. H., Deng, Z., Bullinger, K. L., Nardelli, P., Cope, T. C., &amp; Fyffe, R. E. (2013). Expression of postsynaptic Ca2+&#x2212;activated K+ (SK) channels at C-bouton synapses in mammalian lumbar-motoneurons. Journal of Physiology (London), 591, 875-897.</Citation></Reference><Reference><Citation>Deardorff, A. S., Romer, S. H., Sonner, P. M., &amp; Fyffe, R. E. (2014). Swimming against the tide: investigations of the C-bouton synapse. Front Neural Circuits, 8, 106.</Citation></Reference><Reference><Citation>DeCoster, M. A., Klette, K. L., Knight, E. S., &amp; Tortella, F. C. (1995). Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Research, 671, 45-53.</Citation></Reference><Reference><Citation>DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., &#x2026; Rademakers, R. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-Linked FTD and ALS. Neuron, 72, 245-256. https://doi.org/10.1016/j.neuron.2011.09.011</Citation></Reference><Reference><Citation>Dreser, A., Vollrath, J. T., Sechi, A., Johann, S., Roos, A., Yamoah, A., &#x2026; Goswami, A. (2017). The ALS-linked E102Q mutation in Sigma receptor-1 leads to ER stress-mediated defects in protein homeostasis and dysregulation of RNA-binding proteins. Cell Death and Differentiation, 24, 1655-1671. https://doi.org/10.1038/cdd.2017.88</Citation></Reference><Reference><Citation>Dukkipati, S. S., Chihi, A., Wang, Y., &amp; Elbasiouny, S. M. (2017). Experimental design and data analysis issues contribute to inconsistent results of C-bouton changes in amyotrophic lateral sclerosis. eNeuro, 4(1). ENEURO.0281-16.2016</Citation></Reference><Reference><Citation>Dussossoy, D., Carayon, P., Belugou, S., Feraut, D., Bord, A., Goubet, C., &#x2026; Casellas, P. (1999). Colocalization of sterol isomerase and sigma(1) receptor at endoplasmic reticulum and nuclear envelope level. European Journal of Biochemistry, 263, 377-386.</Citation></Reference><Reference><Citation>Edaravone (MCI-186) ALS 19 Study Group. (2017). Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurology, 16, 505-512.</Citation></Reference><Reference><Citation>Fil, D., DeLoach, A., Yadav, S., Alkam, D., MacNicol, M., Singh, A., &#x2026; Kiaei, M. (2017). Mutant Profilin1 transgenic mice recapitulate cardinal features of motor neuron disease. Human Molecular Genetics, 26, 686-701. https://doi.org/10.1093/hmg/ddw429</Citation></Reference><Reference><Citation>Filadi, R., Greotti, E., Turacchio, G., Luini, A., Pozzan, T., &amp; Pizzo, P. (2016). Presenilin 2 modulates endoplasmic reticulum-mitochondria coupling by tuning the antagonistic effect of mitofusin 2. Cell Reports, 15, 2226-2238.</Citation></Reference><Reference><Citation>Filadi, R., Leal, N. S., Schreiner, B., Rossi, A., Dentoni, G., Pinho, C. M., &#x2026; Ankarcrona, M. (2018). TOM70 sustains cell bioenergetics by promoting IP3R3-mediated ER to mitochondria Ca(2+) transfer. Current Biology, 28, 369-382.</Citation></Reference><Reference><Citation>Fischer, L. R., Culver, D. G., Tennant, P., Davis, A. A., Wang, M., Castellano-Sanchez, A., &#x2026; Glass, J. D. (2004). Amyotrophic lateral sclerosis is a distal axonopathy: Evidence in mice and man. Experimental Neurology, 185, 232-240.</Citation></Reference><Reference><Citation>Fratta, P., Birsa, N., Tosolini, A. P., &amp; Schiavo, G. (2020). Travelling together: A unifying pathomechanism for ALS. Trends in Neurosciences, 43, 1-2.</Citation></Reference><Reference><Citation>Fukunaga, K., Shinoda, Y., &amp; Tagashira, H. (2015). The role of SIGMAR1 gene mutation and mitochondrial dysfunction in amyotrophic lateral sclerosis. Journal of Pharmacological Sciences, 127, 136.</Citation></Reference><Reference><Citation>Futatsugi, A., Ebisui, E., &amp; Mikoshiba, K. (2008). Type 2 and type 3 inositol 1,4,5-trisphosphate (IP3) receptors promote the differentiation of granule cell precursors in the postnatal cerebellum. Journal of Neurochemistry, 105, 1153-1164. https://doi.org/10.1111/j.1471-4159.2008.05221.x</Citation></Reference><Reference><Citation>Gallart-Palau, X., Tarabal, O., Casanovas, A., S&#xe1;bado, J., Correa, F. J., Hereu, M., &#x2026; Esquerda, J. E. (2014). Neuregulin-1 is concentrated in the postsynaptic subsurface cistern of C-bouton inputs to a-motoneurons and altered during motoneuron diseases. The FASEB Journal, 28, 3618-3632. https://doi.org/10.1096/fj.13-248583</Citation></Reference><Reference><Citation>Galmes, R., Houcine, A., Van Vliet, A. R., Agostinis, P., Jackson, C. L., &amp; Giordano, F. (2016). ORP5/ORP8 localize to endoplasmic reticulum-mitochondria contacts and are involved in mitochondrial function. EMBO Reports, 17, 800-810. https://doi.org/10.15252/embr.201541108</Citation></Reference><Reference><Citation>Goguadze, N., Zhuravliova, E., Morin, D., Mikeladze, D., &amp; Maurice, T. (2019). Sigma-1 receptor agonists induce oxidative stress in mitochondria and enhance complex I activity in physiological condition but protect against pathological oxidative stress. Neurotoxicity Research, 35, 1-18.</Citation></Reference><Reference><Citation>Gomez-Suaga, P., Paillusson, S., Stoica, R., Noble, W., Hanger, D. P., &amp; Miller, C. C. J. (2017). The ER-mitochondria tethering complex VAPB-PTPIP51 regulates autophagy. Current Biology, 27, 371-385.</Citation></Reference><Reference><Citation>Gordon, D., Dafinca, R., Scaber, J., Alegre-Abarrategui, J., Farrimond, L., Scott, C., &#x2026; Talbot, K. (2019). Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction. Neurobiology of Disease, 121, 148-162. https://doi.org/10.1016/j.nbd.2018.09.024</Citation></Reference><Reference><Citation>Goswami, A., Jesse, C. M., Chandrasekar, A., Bushuven, E., Vollrath, J. T., Dreser, A., &#x2026; Weis, J. (2015). Accumulation of STIM1 is associated with the degenerative muscle fibre phenotype in ALS and other neurogenic atrophies. Neuropathology and Applied Neurobiology, 41, 304-318.</Citation></Reference><Reference><Citation>Gregianin, E., Pallafacchina, G., Zanin, S., Crippa, V., Rusmini, P., Poletti, A., &#x2026; Vazza, G. (2016). Loss-of-function mutations in the SIGMAR1 gene cause distal hereditary motor neuropathy by impairing ER-mitochondria tethering and Ca2+ signalling. Human Molecular Genetics, 25, 3741-3753. https://doi.org/10.1093/hmg/ddw220</Citation></Reference><Reference><Citation>Griesmaier, E., Posod, A., Gross, M., Neubauer, V., Wegleiter, K., Hermann, M., &#x2026; Kiechl-Kohlendorfer, U. (2012). Neuroprotective effects of the sigma-1 receptor ligand PRE-084 against excitotoxic perinatal brain injury in newborn mice. Experimental Neurology, 237, 388-395. https://doi.org/10.1016/j.expneurol.2012.06.030</Citation></Reference><Reference><Citation>Guzm&#xe1;n-Lenis, M. S., Navarro, X., &amp; Casas, C. (2009). Selective sigma receptor agonist PRE084 promotes neuroprotection and neurite elongation through PKC signaling. Neuroscience, 162, 31-38.</Citation></Reference><Reference><Citation>Hall, A. A., Herrera, Y., Ajmo, C. T. Jr., Cuevas, J., &amp; Pennypacker, K. R. (2009). Sigma receptors suppress multiple aspects of microglial activation. Glia, 57, 744-754.</Citation></Reference><Reference><Citation>Hanner, M., Moebius, F. F., Flandorfer, A., Knaus, H. G., Striessnig, J., Kempner, E., &amp; Glossmann, H. (1996). Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proceedings of the National Academy of Sciences of the United States of America, 93, 8072-8077. https://doi.org/10.1073/pnas.93.15.8072</Citation></Reference><Reference><Citation>Hardiman, O., Al-Chalabi, A., Chio, A., Corr, E. M., Logroscino, G., Robberecht, W., &#x2026; van den Berg, L. H. (2017). Amyotrophic lateral sclerosis. Nat Rev Dis Primers, 5(3), 17071.</Citation></Reference><Reference><Citation>Hayashi, T., Rizzuto, R., Hajnoczky, G., &amp; Su, T. P. (2009). MAM: More than just a housekeeper. Trends in Cell Biology, 19, 81-88. https://doi.org/10.1016/j.tcb.2008.12.002</Citation></Reference><Reference><Citation>Hayashi, T., &amp; Su, T. P. (2007). Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell, 131, 596-610. https://doi.org/10.1016/j.cell.2007.08.036</Citation></Reference><Reference><Citation>Hellstr&#xf6;m, J., Oliveira, A. L. R., Meister, B., &amp; Cullheim, S. (2003). Large cholinergic nerve terminals on subsets of motoneurons and their relation to muscarinic receptor type 2. The Journal of Comparative Neurology, 460, 476-486. https://doi.org/10.1002/cne.10648</Citation></Reference><Reference><Citation>Henkel, J. S., Engelhardt, J. I., Sikl&#xf3;s, L., Simpson, E. P., Kim, S. H., Pan, T., &#x2026; Appel, S. H. (2004). Presence of dendritic cells, MCP-1, and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Annals of Neurology, 55, 221-235. https://doi.org/10.1002/ana.10805</Citation></Reference><Reference><Citation>Hetz, C., Thielen, P., Matus, S., Nassif, M., Court, F., Kiffin, R., &#x2026; Glimcher, L. H. (2009). XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes &amp; Development, 23, 2294-2306.</Citation></Reference><Reference><Citation>Hong, J., Sha, S., Zhou, L., Wang, C., Yin, J., &amp; Chen, L. (2015). Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons. Cell Death &amp; Disease, 6, e1832. https://doi.org/10.1038/cddis.2015.194</Citation></Reference><Reference><Citation>Ince, P. G., Highley, J. R., Kirby, J., Wharton, S. B., Takahashi, H., Strong, M. J., &amp; Shaw, P. J. (2011). Molecular pathology and genetic advances in amyotrophic lateral sclerosis: An emerging molecular pathway and the significance of glial pathology. Acta Neuropathologica, 122, 657-671.</Citation></Reference><Reference><Citation>Ionescu, A., Gradus, T., Altman, T., Maimon, R., Saraf Avraham, N., Geva, M., &#x2026; Perlson, E. (2019). Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model. Cell Death &amp; Disease, 10(3), 210. https://doi.org/10.1038/s41419-019-1451-2</Citation></Reference><Reference><Citation>Jaiswal, M. K. (2014). Selective vulnerability of motoneuron and perturbed mitochondrial calcium homeostasis in amyotrophic lateral sclerosis: Implications for motoneurons specific calcium dysregulation. Mol Cell Ther, 2, 26.</Citation></Reference><Reference><Citation>Kaufman, R. J., &amp; Malhotra, J. D. (2014). Calcium trafficking integrates ER function with mitochondrial bioenergetics. Biochimica et Biophysica Acta, 1843, 2233-2239. https://doi.org/10.1016/j.bbamcr.2014.03.022</Citation></Reference><Reference><Citation>Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., &#x2026; Zoing, M. C. (2011). Amyotrophic lateral sclerosis. Lancet, 377, 942-955.</Citation></Reference><Reference><Citation>Kim, F. J., &amp; Maher, C. M. (2017). Sigma1 pharmacology in the context of cancer. Handbook of Experimental Pharmacology, 244, 237-308.</Citation></Reference><Reference><Citation>Kuhle, J., Lindberg, R. L., Regeniter, A., Mehling, M., Steck, A. J., Kappos, L., &amp; Czaplinski, A. (2009). Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. European Journal of Neurology, 16, 771-774. https://doi.org/10.1111/j.1468-1331.2009.02560.x</Citation></Reference><Reference><Citation>Lahiri, S., Toulmay, A., &amp; Prinz, W. A. (2015). Membrane contact sites, gateways for lipid homeostasis. Current Opinion in Cell Biology, 33, 82-87.</Citation></Reference><Reference><Citation>Langa, F., Codony, X., Tovar, V., Lavado, A., Gim&#xe9;nez, E., Cozar, P., &#x2026; Montoliu, L. (2003). Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. The European Journal of Neuroscience, 18, 2188-2196. https://doi.org/10.1046/j.1460-9568.2003.02950.x</Citation></Reference><Reference><Citation>Laslo, P., Lipski, J., Nicholson, L. F., Miles, G. B., &amp; Funk, G. D. (2001). GluR2 AMPA receptor subunit expression in motoneurons at low and high risk for degeneration in amyotrophic lateral sclerosis. Experimental Neurology, 169, 461-471.</Citation></Reference><Reference><Citation>Lee, J. J. Y., van Karnebeek, C. D. M., Dr&#xf6;gemoller, B., Shyr, C., Tarailo-Graovac, M., Eydoux, P., &#x2026; Wu, J. K. (2016). Further validation of the SIGMAR1 c.151+1G&gt;T mutation as cause of distal hereditary motor neuropathy. Child Neurol Open, 3, 2329048X16669912</Citation></Reference><Reference><Citation>Li, X., Hu, Z., Liu, L., Xie, Y., Zhan, Y., Zi, X., &#x2026; Zhang, R. (2015). A SIGMAR1 splice-site mutation causes distal hereditary motor neuropathy. Neurology, 84, 2430-2437.</Citation></Reference><Reference><Citation>Liu, Y., Pattamatta, A., Zu, T., Reid, T., Bardhi, O., Borchelt, D. R., &#x2026; Ranum, L. P. W. (2016). C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron, 90, 521-534. https://doi.org/10.1016/j.neuron.2016.04.005</Citation></Reference><Reference><Citation>Lockhart, B. P., Soulard, P., Benicourt, C., Privat, A., &amp; Junien, J. L. (1995). Distinct neuroprotective profiles for sigma ligands against N-methyl-d-aspartate (NMDA), and hypoxia-mediated neurotoxicity in neuronal culture toxicity studies. Brain Research, 675, 110-120. https://doi.org/10.1016/0006-8993(95)00049-V</Citation></Reference><Reference><Citation>Ludolph, A. C., Bendotti, C., Blaugrund, E., Chio, A., Greensmith, L., Loeffler, J. P., &#x2026; von Horsten, S. (2010). Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lat Scler, 11, 38-45. https://doi.org/10.3109/17482960903545334</Citation></Reference><Reference><Citation>Ludolph, A. C., &amp; Jesse, S. (2009). Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials. Therapeutic Advances in Neurological Disorders, 2, 319-326.</Citation></Reference><Reference><Citation>Luty, A. A., Kwok, J. B., Dobson-Stone, C., Loy, C. T., Coupland, K. G., Karlstr&#xf6;m, H., &#x2026; Schofield, P. R. (2010). Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Annals of Neurology, 68, 639-649. https://doi.org/10.1002/ana.22274</Citation></Reference><Reference><Citation>Madeo, F., Eisenberg, T., &amp; Kroemer, G. (2009). Autophagy for the avoidance of neurodegeneration. Genes &amp; Development, 23, 2253-2259.</Citation></Reference><Reference><Citation>Mancuso, R., &amp; Navarro, X. (2015). Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. Progress in Neurobiology, 133, 1-26.</Citation></Reference><Reference><Citation>Mancuso, R., Oliv&#xe1;n, S., Osta, R., &amp; Navarro, X. (2011). Evolution of gait abnormalities in SOD1(G93A) transgenic mice. Brain Research, 1406, 65-73.</Citation></Reference><Reference><Citation>Mancuso, R., Oliv&#xe1;n, S., Rando, A., Casas, C., Osta, R., &amp; Navarro, X. (2012). Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics, 9, 814-826. https://doi.org/10.1007/s13311-012-0140-y</Citation></Reference><Reference><Citation>Mancuso, R., Santos-Nogueira, E., Osta, R., &amp; Navarro, X. (2011). Electrophysiological analysis of a murine model of motoneuron disease. Clinical Neurophysiology, 122, 1660-1670.</Citation></Reference><Reference><Citation>Manfredi, G., &amp; Kawamata, H. (2016). Mitochondria and endoplasmic reticulum crosstalk in amyotrophic lateral sclerosis. Neurobiology of Disease, 90, 35-42.</Citation></Reference><Reference><Citation>Marchi, S., &amp; Pinton, P. (2014). The mitochondrial calcium uniporter complex: Molecular components, structure and physiopathological implications. The Journal of Physiology, 592, 829-839. https://doi.org/10.1113/jphysiol.2013.268235</Citation></Reference><Reference><Citation>Martin, L. J., Chen, K., &amp; Liu, Z. (2005). Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. The Journal of Neuroscience, 25, 6449-6459.</Citation></Reference><Reference><Citation>Mart&#xed;nez-Muriana, A., Mancuso, R., Francos-Quijorna, I., Olmos-Alonso, A., Osta, R., Perry, V. H., &#x2026; L&#xf3;pez-Vales, R. (2016). CSF1R blockade slows the progression of amyotrophic lateral sclerosis by reducing microgliosis and invasion of macrophages into peripheral nerves. Scientific Reports, 6, 25663.</Citation></Reference><Reference><Citation>Maurice, T., &amp; Goguadze, N. (2017). Sigma-1 (&#x3c3;1) receptor in memory and neurodegenerative diseases. Handbook of Experimental Pharmacology, 244, 81-108.</Citation></Reference><Reference><Citation>Maurice, T., &amp; Su, T.-P. (2009). The pharmacology of sigma-1 receptors. Pharmacology &amp; Therapeutics, 124, 195-206.</Citation></Reference><Reference><Citation>Mavlyutov, T. A., Epstein, M. L., Andersen, K. A., Ziskind-Conhaim, L., &amp; Ruoho, A. E. (2010). The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience, 167(2), 247-255.</Citation></Reference><Reference><Citation>Mavlyutov, T. A., Epstein, M. L., Liu, P., Verbny, Y. I., Ziskind-Conhaim, L., &amp; Ruoho, A. E. (2012). Development of the sigma-1 receptor in C terminals of motoneurons and colocalization with the N,N&#x2032;dimethyltryptamine forming enzyme, indole-N-methyl transferase. Neuroscience, 206, 60-68. https://doi.org/10.1016/j.neuroscience.2011.12.040</Citation></Reference><Reference><Citation>Mavlyutov, T. A., Epstein, M. L., Verbny, Y. I., Huerta, M. S., Zaitoun, I., Ziskind-Conhaim, L., &amp; Ruoho, A. E. (2013). Lack of sigma-1 receptor exacerbates ALS progression in mice. Neuroscience, 240, 129-134.</Citation></Reference><Reference><Citation>Mavlyutov, T. A., Yang, H., Epstein, M. L., Ruoho, A. E., Yang, J., &amp; Guo, L. W. (2017). APEX2-enhanced electron microscopy distinguishes sigma-1 receptor localization in the nucleoplasmic reticulum. Oncotarget, 8(31), 51317-51330.</Citation></Reference><Reference><Citation>McGivern, J. V., Patitucci, T. N., Nord, J. A., Barabas, M. A., Stucky, C. L., &amp; Ebert, A. D. (2013). Spinal muscular atrophy astrocytes exhibit abnormal calcium regulation and reduced growth factor production. Glia, 61, 1418-1428. https://doi.org/10.1002/glia.22522</Citation></Reference><Reference><Citation>Mejzini, R., Flynn, L. L., Pitout, I. L., Fletcher, S., Wilton, S. D., &amp; Akkari, P. A. (2019). ALS genetics, mechanisms, and therapeutics: Where are we now? Frontiers in Neuroscience, 13, 1310. https://doi.org/10.3389/fnins.2019.01310</Citation></Reference><Reference><Citation>Mendes, C. C., Gomes, D. A., Thompson, M., Souto, N. C., Goes, T. S., Goes, A. M., &#x2026; Leite, M. F. (2005). The type III inositol 1,4,5-trisphosphate receptor preferentially transmits apoptotic Ca2+ signals into mitochondria. The Journal of Biological Chemistry, 280, 40892-40900. https://doi.org/10.1074/jbc.M506623200</Citation></Reference><Reference><Citation>Miles, G. B., Hartley, R., Todd, A. J., &amp; Brownstone, R. M. (2007). Spinal cholinergic interneurons regulate the excitability of motoneurons during locomotion. Proc Natl Acad Sci USA, 104, 2448-2453. https://doi.org/10.1073/pnas.0611134104</Citation></Reference><Reference><Citation>Moon, J. Y., Roh, D. H., Yoon, S. Y., Choi, S. R., Kwon, S. G., Choi, H. S., &#x2026; Lee, J. H. (2014). &#x3c3;1 receptors activate astrocytes via p38 MAPK phosphorylation leading to the development of mechanical allodynia in a mouse model of neuropathic pain. British Journal of Pharmacology, 171, 5881-5897. https://doi.org/10.1111/bph.12893</Citation></Reference><Reference><Citation>Mori, T., Hayashi, T., Hayashi, E., &amp; Su, T. P. (2013). Sigma-1 receptor chaperone at the ER-mitochondrion interface mediates the mitochondrion-ER-nucleus signaling for cellular survival. PLoS ONE, 8(10), e76941.</Citation></Reference><Reference><Citation>Muennich, E. A. L., &amp; Fyffe, R. E. (2004). Focal aggregation of voltage-gated, Kv2.1 subunit containing, potassium channels at synaptic sites in rat spinal motoneurones. Journal of Physiology (London), 554, 673-685. https://doi.org/10.1113/jphysiol.2003.056192</Citation></Reference><Reference><Citation>Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., &amp; Przedborski, S. (2007). Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nature Neurosci, 10, 615-622.</Citation></Reference><Reference><Citation>Nagao, M., Misawa, H., Kato, S., &amp; Hirai, S. (1998). Loss of cholinergic synapses on the spinal motor neurons of amyotrophic lateral sclerosis. Journal of Neuropathology and Experimental Neurology, 57, 329-333. https://doi.org/10.1097/00005072-199804000-00004</Citation></Reference><Reference><Citation>Nguyen, L., Lucke-Wold, B. P., Mookerjee, S., Kaushal, N., &amp; Matsumoto, R. R. (2017). Sigma-1 receptors and neurodegenerative diseases: Towards a hypothesis of Sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection. Advances in Experimental Medicine and Biology, 964, 133-152.</Citation></Reference><Reference><Citation>Ono, Y., Tanaka, H., Takata, M., Nagahara, Y., Noda, Y., Tsuruma, K., &#x2026; Hara, H. (2014). SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models. Neuroscience Letters, 559, 174-178.</Citation></Reference><Reference><Citation>O'Rourke, J. G., Bogdanik, L., Muhammad, A. K. M. G., Gendron, T. F., Kim, K. J., Austin, A., &#x2026; Baloh, R. H. (2015). C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron, 88(5), 892-901.</Citation></Reference><Reference><Citation>Ortega, J. A., Daley, E. L., Kour, S., Samani, M., Tellez, L., Smith, H. S., &#x2026; Kiskinis, E. (2020). Nucleocytoplasmic proteomic analysis uncovers eRF1 and nonsense-mediated decay as modifiers of ALS/FTD C9orf72 toxicity. Neuron, 106(1), 90-107. https://doi.org/10.1016/j.neuron.2020.01.020</Citation></Reference><Reference><Citation>Pabba, M., Wong, A. Y., Ahlskog, N., Hristova, E., Biscaro, D., Nassrallah, W., &#x2026; Bergeron, R. (2014). NMDA receptors are upregulated and trafficked to the plasma membrane after sigma-1 receptor activation in the rat hippocampus. The Journal of Neuroscience, 34(34), 11325-11338. https://doi.org/10.1523/JNEUROSCI.0458-14.2014</Citation></Reference><Reference><Citation>Paillusson, S., Stoica, R., Gomez-Suaga, P., Lau, D. H. W., Mueller, S., Miller, T., &amp; Miller, C. C. J. (2016). There's something wrong with my MAM; the ER-mitochondria axis and neurodegenerative diseases. Trends in Neurosciences, 39, 146-157. https://doi.org/10.1016/j.tins.2016.01.008</Citation></Reference><Reference><Citation>Penas, C., Pascual-Font, A., Mancuso, R., For&#xe9;s, J., Casas, C., &amp; Navarro, X. (2011). Sigma receptor agonist 2-(4-morpholinethyl)1-phenylcyclohexanecarboxylate (PRE084) increases GDNF and BIP expression and promotes neuroprotection after root avulsion injury. Journal of Neurotrauma, 28, 831-840.</Citation></Reference><Reference><Citation>Peters, O. M., Cabrera, G. T., Tran, H., Gendron, T. F., McKeon, J. E., Metterville, J., &#x2026; Brown, R. H. Jr (2015). Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron, 88, 902-909.</Citation></Reference><Reference><Citation>Petrov, D., Mansfield, C., Moussy, A., &amp; Hermine, O. (2017). ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci, 22(9), 68.</Citation></Reference><Reference><Citation>Peviani, M., Salvaneschi, E., Bontempi, L., Petese, A., Manzo, A., Rossi, D., &#x2026; Curti, D. (2014). Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiology of Disease, 62, 218-232. https://doi.org/10.1016/j.nbd.2013.10.010</Citation></Reference><Reference><Citation>Pinton, P., Giorgi, C., Siviero, R., Zecchini, E., &amp; Rizzuto, R. (2008). Calcium and apoptosis: ER-mitochondria Ca2+ transfer in the control of apoptosis. Oncogene, 27, 6407-6418.</Citation></Reference><Reference><Citation>Prause, J., Goswami, A., Katona, I., Roos, A., Schnizler, M., Bushuven, E., &#x2026; Weis, J. (2013). Altered localization, abnormal modification and loss of function of Sigma receptor-1 in amyotrophic lateral sclerosis. Human Molecular Genetics, 22, 1581-1600.</Citation></Reference><Reference><Citation>Prell, T., Lautenschl&#xe4;ger, J., Witte, O. W., Carri, M. T., &amp; Grosskreutz, J. (2012). The unfolded protein response in models of human mutant G93A amyotrophic lateral sclerosis. The European Journal of Neuroscience, 35, 652-660.</Citation></Reference><Reference><Citation>Pun, S., Santos, A. F., Saxena, S., Xu, L., &amp; Caroni, P. (2006). Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nature Neuroscience, 9, 408-419. https://doi.org/10.1038/nn1653</Citation></Reference><Reference><Citation>Renton, A. E., Chi&#xf2;, A., &amp; Traynor, B. J. (2014). State of play in amyotrophic lateral sclerosis genetics. Nature Neuroscience, 17, 17-23. https://doi.org/10.1038/nn.3584</Citation></Reference><Reference><Citation>Ripps, M. E., Huntley, G. W., Hof, P. R., Morrison, J. H., &amp; Gordon, J. W. (1995). Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA, 92, 689-693. https://doi.org/10.1073/pnas.92.3.689</Citation></Reference><Reference><Citation>Rodr&#xed;guez-Mu&#xf1;oz, M., S&#xe1;nchez-Bl&#xe1;zquez, P., Herrero-Labrador, R., Mart&#xed;nez-Murillo, R., Merlos, M., Vela, J. M., &amp; Garz&#xf3;n, J. (2015). The &#x3c3;1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control. Antioxidants &amp; Redox Signaling, 22, 799-818. https://doi.org/10.1089/ars.2014.5993</Citation></Reference><Reference><Citation>Ryskamp, D. A., Zhemkov, V., &amp; Bezprozvanny, I. (2019). Mutational analysis of Sigma-1 receptor's role in synaptic stability. Frontiers in Neuroscience, 13, 1012. https://doi.org/10.3389/fnins.2019.01012</Citation></Reference><Reference><Citation>S&#xe1;nchez-Bl&#xe1;zquez, P., Pozo-Rodrig&#xe1;lvarez, A., Merlos, M., &amp; Garz&#xf3;n, J. (2018). The Sigma-1 receptor antagonist, S1RA, reduces stroke damage, ameliorates post-stroke neurological deficits and suppresses the overexpression of MMP-9. Molecular Neurobiology, 55, 4940-4951.</Citation></Reference><Reference><Citation>Saxena, S., Roselli, F., Singh, K., Leptien, K., Julien, J. P., Gros-Louis, F., &amp; Caroni, P. (2013). Neuroprotection through excitability and mTOR required in ALS motoneurons to delay disease and extend survival. Neuron, 80, 80-96. https://doi.org/10.1016/j.neuron.2013.07.027</Citation></Reference><Reference><Citation>Schmidt, H. R., Zheng, S., Gurpinar, E., Koehl, A., Manglik, A., &amp; Kruse, A. C. (2016). Crystal structure of the human &#x3c3;1 receptor. Nature, 532(7600), 527-530.</Citation></Reference><Reference><Citation>Schumacher, M. A., Rivard, A. F., B&#xe4;chinger, H. P., &amp; Adelman, J. P. (2001). Structure of the gating domain of a Ca2+&#x2212;activated K+ channel complexed with Ca2+/calmodulin. Nature, 410, 1120-1124.</Citation></Reference><Reference><Citation>Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., et al. (2008). Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lat Scler, 9, 4-15.</Citation></Reference><Reference><Citation>Sha, S., Qu, W. J., Li, L., Lu, Z. H., Chen, L., Yu, W. F., &amp; Chen, L. (2013). Sigma-1 receptor knockout impairs neurogenesis in dentate gyrus of adult hippocampus via down-regulation of NMDA receptors. CNS Neuroscience &amp; Therapeutics, 19, 705-713. https://doi.org/10.1111/cns.12129</Citation></Reference><Reference><Citation>Shen, Y. C., Wang, Y. H., Chou, Y. C., Liou, K. T., Yen, J. C., Wang, W. Y., &#x2026; Liao, J. F. (2008). Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation. Journal of Neurochemistry, 104, 558-572.</Citation></Reference><Reference><Citation>Shimazu, S., Katsuki, H., Takenaka, C., Tomita, M., Kume, T., Kaneko, S., &amp; Akaike, A. (2000). A. Sigma receptor ligands attenuate N-methyl-d-aspartate cytotoxicity in dopaminergic neurons of mesencephalic slice cultures. European Journal of Pharmacology, 388, 139-146.</Citation></Reference><Reference><Citation>Simmen, T., Aslan, J. E., Blagoveshchenskaya, A. D., Thomas, L., Wan, L., Xiang, Y., &#x2026; Thomas, G. (2005). PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. The EMBO Journal, 24, 717-729. https://doi.org/10.1038/sj.emboj.7600559</Citation></Reference><Reference><Citation>Sleigh, J. N., Rossor, A. M., Fellows, A. D., Tosolini, A. P., &amp; Schiavo, G. (2019). Axonal transport and neurological disease. Nature Reviews. Neurology, 15, 691-703. https://doi.org/10.1038/s41582-019-0257-2</Citation></Reference><Reference><Citation>Smith, K. J., Butler, T. R., &amp; Prendergast, M. A. (2010). Inhibition of &#x3c3;1R reduces N-methyl-d-aspartate induced neuronal injury in methamphetamine-exposed and -naive hippocampi. Neuroscience Letters, 481, 144-148. https://doi.org/10.1016/j.neulet.2010.06.069</Citation></Reference><Reference><Citation>Soulard, C., Salsac, C., Mouzat, K., Hilaire, C., Roussel, J., Mezghrani, A., &#x2026; Scamps, F. (2020). Spinal motoneuron TMEM16F acts at C-boutons to modulate motor resistance and contributes to ALS pathogenesis. Cell Reports, 30, 2581-2593.</Citation></Reference><Reference><Citation>Spalloni, A., Nutini, M., &amp; Longone, P. (2013). Role of the N-methyl-d-aspartate receptors complex in amyotrophic lateral sclerosis. Biochimica et Biophysica Acta, 1832, 312-322. https://doi.org/10.1016/j.bbadis.2012.11.013</Citation></Reference><Reference><Citation>Srivats, S., Balasuriya, D., Pasche, M., Vistal, G., Edwardson, J. M., Taylor, C. W., &amp; Murrell-Lagnado, R. D. (2016). Sigma1 receptors inhibit store-operated Ca2+ entry by attenuating coupling of STIM1 to Orai1. The Journal of Cell Biology, 213, 65-79. https://doi.org/10.1083/jcb.201506022</Citation></Reference><Reference><Citation>Stoica, R., De Vos, K. J., Paillusson, S., Mueller, S., Sancho, R. M., Lau, K. F., &#x2026; Miller, C. C. J. (2014). ER-mitochondria associations are regulated by the VAPB-TPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nature Communications, 5, 3996. https://doi.org/10.1038/ncomms4996</Citation></Reference><Reference><Citation>Stoica, R., Paillusson, S., Gomez-Suaga, P., Mitchell, J. C., Lau, D. H., Gray, E. H., &#x2026; Miller, C. C. (2016). ALS/FTD-associated FUS activates GSK-3&#x3b2; to disrupt the VAPB-PTPIP51 interaction and ER mitochondria associations. EMBO Reports, 17, 1326-1342.</Citation></Reference><Reference><Citation>Szabadkai, G., Bianchi, K., V&#xe1;rnai, P., De Stefani, D., Wieckowski, M. R., Cavagna, D., &#x2026; Rizzuto, R. (2006). Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. The Journal of Cell Biology, 175, 901-911.</Citation></Reference><Reference><Citation>Tadi&#x107;, V., Malci, A., Goldhammer, N., Stubendorff, B., Sengupta, S., Prell, T., &#x2026; Grosskreutz, J. (2017). Sigma 1 receptor activation modifies intracellular calcium exchange in the G93A(hSOD1) ALS model. Neuroscience, 359, 105-118. https://doi.org/10.1016/j.neuroscience.2017.07.012</Citation></Reference><Reference><Citation>Tsai, S. Y., Chuang, J. Y., Tsai, M. S., Wang, X. F., Xi, Z. X., Hung, J. J., &#x2026; Su, T. P. (2015). Sigma-1 receptor mediates cocaine-induced transcriptional regulation by recruiting chromatin-remodeling factors at the nuclear envelope. Proceedings of the National Academy of Sciences of the United States of America, 112, E6562-E6570.</Citation></Reference><Reference><Citation>Tu, P. H., Raju, P., Robinson, K. A., Gurney, M. E., Trojanowski, J. Q., &amp; Lee, V. M. (1996). Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci USA, 93, 3155-3160. https://doi.org/10.1073/pnas.93.7.3155</Citation></Reference><Reference><Citation>Turner, B., &amp; Talbot, K. (2008). Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Progress in Neurobiology, 85, 94-134. https://doi.org/10.1016/j.pneurobio.2008.01.001</Citation></Reference><Reference><Citation>Vagnerova, K., Hurn, P. D., Bhardwaj, A., &amp; Kirsch, J. R. (2006). Sigma 1 receptor agonists act as neuroprotective drugs through inhibition of inducible nitric oxide synthase. Anesthesia and Analgesia, 103, 430-434.</Citation></Reference><Reference><Citation>Vavers, E., Svalbe, B., Lauberte, L., Stonans, I., Misane, I., Dambrova, M., &amp; Zvejniece, L. (2017). The activity of selective sigma-1 receptor ligands in seizure models in vivo. Behavioural Brain Research, 328, 13-18.</Citation></Reference><Reference><Citation>Ververis, A., Dajani, R., Koutsou, P., Aloqaily, A., Nelson-Williams, C., Loring, E., &#x2026; Christodoulou, K. (2020). Distal hereditary motor neuronopathy of the Jerash type is caused by a novel SIGMAR1 c.500A&gt;T missense mutation. Journal of Medical Genetics, 57, 178-186.</Citation></Reference><Reference><Citation>Villalpando-Rodriguez, G. E., &amp; Torriglia, A. (2013). Calpain 1 induce lysosomal permeabilization by cleavage of lysosomal associated membrane protein 2. Biochimica et Biophysica Acta, 1833, 2244-2253. https://doi.org/10.1016/j.bbamcr.2013.05.019</Citation></Reference><Reference><Citation>Vinay, L., Brocard, F., Pflieger, J. F., Simeoni-Alias, J., &amp; Clarac, F. (2000). Perinatal development of lumbar motoneurons and their inputs in the rat. Brain Research Bulletin, 53, 635-647.</Citation></Reference><Reference><Citation>Wang, Y., &amp; Zhao, C. S. (2019). Sigma-1 receptor activation ameliorates LPS-induced NO production and ROS formation through the Nrf2/HO-1 signaling pathway in cultured astrocytes. Neuroscience Letters, 711, 134387.</Citation></Reference><Reference><Citation>Watanabe, S., Hayakawa, T., Wakasugi, K., &amp; Yamanaka, K. (2014). Cystatin C protects neuronal cells against mutant copper-zinc superoxide dismutase-mediated toxicity. Cell Death &amp; Disease, 5, e1497. https://doi.org/10.1038/cddis.2014.459</Citation></Reference><Reference><Citation>Watanabe, S., Ilieva, H., Tamada, H., Nomura, H., Komine, O., Endo, F., &#x2026; Yamanaka, K. (2016). Mitochondria-associated membrane collapse is a common pathomechanism in SIGMAR1- and SOD1-linked ALS. EMBO Molecular Medicine, 8, 1421-1437.</Citation></Reference><Reference><Citation>Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M., &amp; Baloh, R. H. (2009). TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proceedings of the National Academy of Sciences of the United States of America, 106, 18809-18814. https://doi.org/10.1073/pnas.0908767106</Citation></Reference><Reference><Citation>Weng, T. Y., Tsai, S. A., &amp; Su, T. P. (2017). Roles of &#x3c3;1Rs on mitochondrial functions relevant to neurodegenerative diseases. Journal of Biomedical Science, 24, 74. https://doi.org/10.1186/s12929-017-0380-6</Citation></Reference><Reference><Citation>Wong, A. Y., Hristova, E., Ahlskog, N., Tasse, L. A., Ngsee, J. K., &amp; Chudalayandi, P. (2016). Aberrant subcellular dynamics of sigma-1 receptor mutants underlying neuromuscular diseases. Molecular Pharmacology, 90, 238-253.</Citation></Reference><Reference><Citation>Yamamoto, H., Yamamoto, T., Sagi, N., Klenerov&#xe1;, V., Goji, K., Kawai, N., &#x2026; Moroji, T. (1995). Sigma ligands indirectly modulate the NMDA receptor-ion channel complex on intact neuronal cells via sigma 1 site. The Journal of Neuroscience, 15, 731-736.</Citation></Reference><Reference><Citation>Yamashita, T., Hideyama, T., Hachiga, K., Teramoto, S., Takano, J., Iwata, N., &#x2026; Kwak, S. (2012). A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nature Communications, 3, 1307. https://doi.org/10.1038/ncomms2303</Citation></Reference><Reference><Citation>Zagoraiou, L., Akay, T., Martin, J. F., Brownstone, R. M., Jessell, T. M., &amp; Miles, G. B. (2009). A cluster of cholinergic premotor interneurons modulates mouse locomotor activity. Neuron, 64, 645-662.</Citation></Reference><Reference><Citation>Zamanillo, D., Romero, L., Merlos, M., &amp; Vela, J. M. (2013). Sigma 1 receptor: A new therapeutic target for pain. European Journal of Pharmacology, 716(1-3), 78-93. https://doi.org/10.1016/j.ejphar.2013.01.068</Citation></Reference><Reference><Citation>Zhang, X.-J., Liu, L.-L., Jiang, S.-X., Zhong, Y.-M., &amp; Yang, X.-L. (2011). Activation of the &#x3c3; receptor 1 suppresses NMDA responses in rat retinal ganglion cells. Neuroscience, 177, 12-22. https://doi.org/10.1016/j.neuroscience.2010.12.064</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>